Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair

The median survival for patients with locally advanced pancreatic cancer treated with gemcitabine and radiation is approximately one year. To develop improved treatment, we have combined a Chk1/2 targeted agent, AZD7762, currently in Phase I clinical trials, with gemcitabine and ionizing radiation i...

Full description

Saved in:
Bibliographic Details
Main Authors: Morgan, Meredith A., Parsels, Leslie A., Zha, Lili, Parsels, Joshua D., Davis, Mary A., Hassan, Maria C., Arumugarajah, Sankari, Hylander-Gans, Linda, Morosini, Deborah, Simeone, Diane M., Canman, Christine E., Normolle, Daniel P., Zabludoff, Sonya D., Maybaum, Jonathan, Lawrence, Theodore S.
Format: Artigo
Language:Inglês
Published: 2010
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2889008/
https://ncbi.nlm.nih.gov/pubmed/20501833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-3573
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items